Epizyme successfully met with the U.S. Food and Drug Administration (FDA) to bolster an upcoming submission of its oral investigational treatment tazemetostat for relapsed or resistant follicular lymphoma, with ... Read more

Health Canada has expanded its approval of Adcetris (brentuximab vedotin) in combination with a chemotherapy regimen for the first-line treatment of peripheral T-cell lymphomas expressing the CD30 marker. The approval ... Read more

“Oh, by the way,” she said nonchalantly as I entered the room. “Your scans are clear.” “I’m sorry, what?” I stuttered in disbelief. Just like that, in a matter ... Read more

A branch of the European Medicines Agency voiced support for Revlimid (lenalidomide) in combination with rituximab becoming a treatment option for adults with follicular lymphoma who responded poorly to, or whose disease ... Read more

Bristol-Myers Squibb‘s arthritis medicine Orencia (abatacept) has been named Breakthrough Therapy by the U.S. Food and Drug Administration for the prevention of acute graft-versus-host disease (GvHD) in patients who ... Read more

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The agency’s decision was ... Read more

An advisory committee for the European Medicines Agency has recommended the conditional approval of Roche‘s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) and bendamustine (a chemotherapy) for the treatment ... Read more

The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene’s Brukinsa (zanubrutinib) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at ... Read more

The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory ... Read more